Lung Neoplasms  >>  iniparib (BSI 201)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
iniparib (BSI 201) / Sanofi
ECLIPSE, NCT01082549: Trial of Gemcitabine/Carboplatin With or Without Iniparib (SAR240550) (a PARP1 Inhibitor) in Subjects With Previously Untreated Stage IV Squamous Non-Small-Cell Lung Cancer (NSCLC)

Checkmark WCLC 2013
Oct 2013 - Oct 2013: WCLC 2013
Checkmark 1st line squamous NSCLC
Jun 2013 - Jun 2013: 1st line squamous NSCLC
Checkmark P3 data 1st line,Stg IV, NSCLC
More
Completed
3
780
US, Canada, Europe, RoW
gemcitabine/carboplatin, gemcitabine/carboplatin plus Iniparib
Sanofi
Squamous Cell Lung Cancer
04/13
04/13

Download Options